Skip to main content
NewslettersWatchlist

Viridian Therapeutics Inc(VRDN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low13.39
Day High14.76
Open:14.60
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
2 Growth Stocks Wall Street Analysts Think Can Double in Value
Motley Fool
Why Shares of Viridian Therapeutics Are Falling Tuesday
Motley Fool
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning
Spotlight Growth
Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease
Globe Newswire
Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022
Globe Newswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact the Firm
Globe Newswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
Globe Newswire
Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital
Globe Newswire
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Globe Newswire
Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
Globe Newswire
Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
Globe Newswire
Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022
Globe Newswire
Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18
Globe Newswire
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
Globe Newswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
Viridian Therapeutics to Present at Upcoming Investor Conferences
Globe NewsWire
Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association
Globe NewsWire
Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Globe NewsWire
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock
Globe NewsWire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
Globe NewsWire
Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Globe NewsWire
Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference
Globe NewsWire
Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer
Globe NewsWire
Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
Globe NewsWire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe NewsWire
Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Globe NewsWire
Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference
Globe NewsWire
Viridian Therapeutics to Participate in Upcoming Investor Conferences
Globe NewsWire
Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

Profile

Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.